Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$77.69 USD

77.69
1,689,942

+1.02 (1.33%)

Updated Jul 10, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arpita Dutt headshot

4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio

The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.

    Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

    Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

      Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year

      Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.

        Arpita Dutt headshot

        Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused

        Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.

          Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug

          Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.

            J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

            Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.

              AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

              AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

                Intellipharmaceutics Announces Launch of Generic Seroquel XR

                Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company

                  Incyte Provides Updated Data on Cancer Combination Therapies

                  Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.

                    Incyte Announces Data on Enzyme Inhibitor with Keytruda

                    Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.

                      Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

                      Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

                        Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

                        On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

                          Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                          After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                            AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk

                            AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.

                              The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac

                              The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac

                                AstraZeneca Sells Marketing Rights to Seloken in Europe

                                AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.

                                  AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions

                                  AstraZeneca (AZN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

                                    Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

                                    Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

                                      Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

                                      On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

                                        Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

                                        We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

                                          AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

                                          AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

                                            AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

                                            AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

                                              What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                              Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

                                                While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

                                                  Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1

                                                  Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.